Please assess the completion status of the following clinical trial:

Trial Title: An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Flexible Bronchoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patient must be able to understand, either orally or in writing, and be able to consent and complete the required assessments and procedures~2. Patient provides signed/dated Informed Consent and Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization after receiving a full explanation of the extent and nature of the study.~3. Patient must be at least 18 years of age at the time of screening.~4. If female, patient must be surgically sterile, postmenopausal, or not pregnant or lactating and must have been using an acceptable method of birth control for at least 1 month prior to dosing, with a negative urine pregnancy test result at screening and predose.~5. Patient meets American Society of Anesthesiologists (ASA) Physical Classification System status of P1 to P4.~Exclusion Criteria:~1. Patient has a history of allergic reaction or hypersensitivity to any anesthetic agent or opioid.~2. Patient does not meet nils per os (NPO) status per ASA guidelines or institution's guideline.~3. Patient has a Mallampati Classification Score of 4; OR a Mallampati Classification Score of 3 AND a thyromental distance ≤4 cm, or for any other reason has a difficult airway, in the opinion of the Investigator.~4. Patient has an abnormal, clinically significant 3-lead ECG finding at predosing period Day 0.~5. Patient has participated in an investigational drug study within 1 month prior to study start.~6. Patient is unwilling to adhere to pre- and postprocedural instructions.~7. Patient for whom the use of fentanyl citrate injection (fentanyl) is contraindicated.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).